Vivaldi Biosciences is developing Delta NS1 vaccines for protection against epidemic and pandemic viral respiratory diseases. The Delta NS1 vaccine platform is designed to rapidly induce interferon, enhancing immune response without replicating or shedding the virus.

Vivaldi Biosciences

Vivaldi Biosciences | 724 followers on LinkedIn. Developing nasal-spray, self-adjuvanting vaccines: DeltaFLU universal flu vaccine, and Delta-19 universal flu + Covid-19 | Vivaldi Biosciences is developing vaccines for protection against epidemic and pandemic viral respiratory diseases using its Delta NS1 vector and innovative cell-based production technologies. 
Vivaldi’s DeltaFLU universal influenza vaccine is in Phase 2 clinical development. Its Delta-19 universal influenza/Covid-19 vaccine will enter clinical trials in 2021.

Amy Aspelund

Research Associate at Vivaldi Biosciences Inc.

Maxwell Peters

Managing Director at Nuvonis Technologies GmbH

Manfred Reiter

Associate Scientist at Vivaldi Biosciences

Alaura Hoag

#H5N1 continues to make headlines in the US. To help visualize the continuing story, this updated video shows the current reported states with dairy herd infections and the tally of affected cattle as of October 7. Watch here ⤵

Brown University Pandemic Center

25 human cases of #H5N1 #influenza in the US so far this year. Vivaldi's H5N1 nasal-spray vaccine was safe and immunogenic in a Phase 1 clinical trial, with 75% of study volunteers showing seroconversion after a single dose, and 92% showing this antibody response level after 2 doses.

Advantages of nasal-spray #vaccines and how they work are described here. Vivaldi's DeltaFLU universal #influenza vaccine is in development as the first nasal-spray vaccine that protects against all influenza virus strains. https://lnkd.in/ei8kGe23

Vivaldi is developing this game-changer universal flu vaccine: The current vaccines that we have for both influenza and coronavirus are good vaccines—but they're not great. They can reduce serious illness, hospitalizations, and deaths. But protection has a decidedly limited duration, and even if someone gets vaccinated, they could still get infected and transmit the virus. The best of all scenarios would be what we call a game-changer universal vaccine that creates a broad immune response that covers a wide range of flus or coronaviruses.” - Michael Osterholm, PhD, MPH https://lnkd.in/eB-YnWFe

Serving as coordinator of the FLUniversal consortium developing a universal #influenza #vaccine , Zafiro brings strong experience in managing complex EU-financed research & innovation projects.

With its longstanding and well-earned reputation for expertise and excellent service, Vivaldi Biosciences is pleased to partner with MediTox to conduct further nonclinical studies of immunogenicity and protection with our DeltaFLU universal influenza vaccine.

“It is time for all nations to wake up to the danger and prepare for a new pandemic. At the top of the list should be a game-changing improvement in the medical countermeasures that governments put in place to fight influenza viruses and coronaviruses. Specifically, this means vaccines, drug treatments, and diagnostic tests… Of course, it is still possible that such a pandemic may never arise—or that it doesn’t occur for many years. But hope is not a strategy.” https://lnkd.in/eA8JE98C

Excellent Fact Sheet summarizing the H5N1 influenza situation prepared by the Coalition to Stop Flu.

Vivaldi is Biosciences is participating in the 1st annual meeting of the RRPV | Rapid Response Partnership Vehicle in Washington, DC. With clinical-stage #vaccines for universal flu protection and #H5N1 (avian #influenza ), Vivaldi is one of just a small number of vaccine companies accepted for RRPV membership. The RRPV is a consortium formed by the Biomedical Advanced Research and Development Authority (BARDA) to accelerate medical countermeasure product and technology development to address evolving needs including pandemic influenza, emerging infectious diseases, and other biological threats.

Vivaldi is pleased to partner with MHRA, which provides the FLUniversal consortium unique resources and expertise for the clinical challenge study of our DeltaFLU universal #influenza #vaccine .

Metric
Company Name	Vivaldi Biosciences
Symbol
MSH ID	COM:VIVALDIBIOSCIENCES
Market	PRIVATE
Sector	Healthcare & Health Services
Industry	Biotechnology
Country	US
Stage
Employee Count
Website	vivaldibiosciences.com
LinkedIn	vivaldi-biosciences-inc-
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

VIVA

COM:VIVALDIBIOSCIENCES

Vivaldi Biosciences

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue